Metformin and myoinositol for polycystic ovary syndrome: A review of their combined effectiveness
Abstract
Polycystic ovary syndrome (PCOS) is a prevalent endocrine heterogeneous disorder. The complex etiology of PCOS involves hormonal imbalances, genetics, lifestyle, and environmental factors. Insulin resistance is one of the most significant pathophysiological traits in both obese and lean females with PCOS. Both obese and lean women with PCOS are vulnerable to the problem of insulin resistance. The Indian phenotype has been shown to have a predominance of PCOS associated with insulin resistance. Insulin sensitizers improve insulin sensitivity, thereby lowering insulin levels and managing the hormonal and metabolic abnormalities associated with PCOS. Insulin sensitizers like metformin, inositols, and chromium are commonly used in the treatment of PCOS. Metformin and Myoinositol in combination have been found to be synergistically beneficial for alleviating the symptoms of PCOS by enhancing insulin sensitivity at the different targets in the cascade of insulin resistance. Recent data from clinical trials and meta-analysis has highlighted the potential benefits of combining metformin and myoinositol in managing PCOS symptoms such as menstrual irregularity, hyperandrogenism, insulin resistance, and infertility. The aim of this review is to summarize currently available data on the metformin and myoinositol combination therapy in PCOS patients.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.